http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0147335-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0df250cb6f03aa852ae5d4e8225e45dc
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-204
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26
filingDate 1984-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f621229e69fc669ada649b6d61398ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eb9b5df2a64778b9661c1cc8cf4ce1a
publicationDate 1985-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0147335-A2
titleOfInvention Pharmaceutical inert matrix made of polycaprolactone, and method of preparing an oral galenic form
abstract The present invention relates to a new inert matrix having an adjustable porosity and hardness.n n n This matrix comprises polycaprolactone having an average molecular weight of between approximately 2,000 and 70,000 which is in the form of agglomerated grains having an average diameter of between 50 and 500 μm and has a degree of crystallinity of at least 75%. The invention relates to the process for the preparation of a porous dosage form by means of said matrix.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3701625-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8807870-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0275961-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2791569-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0057856-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013084059-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2216411-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0275961-A2
priorityDate 1984-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3929937-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4148871-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2377431-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID166304
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64929
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406563
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129818107
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127451434
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136080371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406888
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2520
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68715
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128633517
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396617
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3339
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129233874

Total number of triples: 41.